NZ 598490 Disclosed is the use of an anti-angiogenic compound of formula (I) as defined in the complete specification or a pharmaceutically acceptable salt, solvate or a disodium phosphate ester prodrug thereof in the manufacture of a medicament for treating macular degeneration (MD) in a patient in need thereof.